<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369355</url>
  </required_header>
  <id_info>
    <org_study_id>CR018421</org_study_id>
    <secondary_id>CNTO1275CRD3003</secondary_id>
    <secondary_id>2010-022760-12</secondary_id>
    <nct_id>NCT01369355</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance
      regimens of ustekinumab administered subcutaneously to patients with moderately to severely
      active Crohn's disease who responded to treatment with intravenous ustekinumab in studies
      CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to determine whether additional ustekinumab treatment is
      beneficial in patients with moderately to severely active Crohn's disease who initially had a
      clinical response to IV ustekinumab in one of the 2 initial induction studies (the
      CNTO1275CRD3001 [&quot;UNITI-1&quot;] or CNTO1275CRD3002 [&quot;UNITI-2&quot;] induction studies). The
      maintenance treatment will be injections in the skin (given subcutaneously, or &quot;SC&quot;) of 90 mg
      ustekinumab either every 8 weeks or 12 weeks, and the effects (both the benefits and any side
      effects or adverse events) will be compared to SC placebo injections (otherwise identical
      except without ustekinumab). Patients who responded to IV ustekinumab in the UNITI-1
      (NCT01369329) or UNITI-2 (NCT01369342) induction studies will be put into one of these 3
      groups by chance (randomly, like rolling dice). The study will be double-blinded (so that
      neither patients nor study personnel know the identity of the assigned treatment). Patients
      who are randomized to either SC placebo or 90mg ustekinumab SC every 12 weeks who experience
      worsening in their Crohn's Disease symptoms (per the study loss of response criteria) will
      have their treatment adjusted so that they will instead start to receive 90mg ustekinumab SC
      every 8 weeks. All patients from the UNITI-1 or UNITI-2 studies (in addition to the patients
      described above who responded to IV ustekinumab) will be eligible to enter this study,
      provided the Week 8 visit in those trials was completed and study requirements are still met.
      Patients who are not in clinical response to IV placebo or ustekinumab in UNITI-1 or UNITI-2
      will receive both IV and SC study agent at the first visit of this study (week 0). Patients
      previously receiving IV placebo will receive ustekinumab 130 mg IV at week 0 (and SC
      placebo), and patients previously receiving IV ustekinumab will receive 90 mg ustekinumab SC
      at week 0 (as well as IV placebo). If these patients are in clinical response 8 weeks later,
      they will receive 90 SC ustekinumab at that week8 visit, and will continue to receive
      Ustekinumab (every 8 weeks for participants not in response to IV Ustekinumab and every 12
      weeks for participants not in response to IV Placebo) throughout the rest of the study
      (provided they otherwise remain eligible). Patients in clinical response to IV placebo
      induction dosing will continue to receive SC placebo. The main part of this study, also
      called the maintenance portion, will last 44 weeks. After week 44, all participants who are
      continuing to do well will be eligible to continue to receive study agent in the second part
      of the study, a long term extension where the study agent will continue to be administered up
      to week 252. Participants who discontinue study agent, either during the study, or after week
      252, will be asked to return for a final safety follow-up visit 20 weeks after they last
      received study agent.

      Patients in response to IV ustekinumab will be randomized to receive either placebo (Group
      1), Ustekinumab 90 mg SC every 12 weeks (Group 2), or Ustekinumab 90mgSC every 8 weeks (Group
      3). If patients in Groups 1 or 2 lose response, they will cross over to receive ustekinumab
      90mg every 8 weeks. Other populations (nonresponders to prior IV ustekinumab or IV placebo)
      will receive ustekinumab at Week0 (either 90mg SC or 130mg IV, respectively) and continue SC
      ustekinumab if in response at Week 8, Placebo IV responders will continue to receive Placebo
      SC q4w.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 13, 2011</start_date>
  <completion_date type="Anticipated">October 21, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Remission at Week 44</measure>
    <time_frame>Week 44</time_frame>
    <description>Clinical remission at Week 44 was defined as a Crohn's Disease Activity Index (CDAI) score of &lt;150 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). CDAI was assessed by collecting information on 8 different Crohn's disease-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). A decrease in CDAI over time indicates improvement in disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Response at Week 44</measure>
    <time_frame>Week 44</time_frame>
    <description>Clinical response at Week 44 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (&gt;=) 100 points. Participants with a baseline CDAI score of &gt; = 220 to less than or equal (&lt; =) 248 were considered to be in clinical response if a CDAI score of less than (&lt;) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Clinical Remission at Week 44 Among Participants in Clinical Remission to Ustekinumab at Week 0 of Maintenance Study</measure>
    <time_frame>Week 44</time_frame>
    <description>Clinical remission at week 44 was defined as a CDAI score of &lt; 150 points among participants in clinical remission to Ustekinumab at week 0 of maintenance study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Corticosteroid-free Remission at Week 44</measure>
    <time_frame>Week 44</time_frame>
    <description>Corticosteroid-free remission at Week 44 was defined as a CDAI score of &lt;150 points without receiving corticosteroids at Week 44.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Clinical Remission at Week 44 in the Subset of Participants Who Were Refractory or Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy</measure>
    <time_frame>Week 44</time_frame>
    <description>Clinical remission at Week 44 was defined as a CDAI score of &lt;150 points in the subset of participants who were refractory or Intolerant to tumor necrosis factor antagonist therapy.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1282</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Colitis</condition>
  <condition>IBD</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>006</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Placebo will be administered subcutaneously.</description>
    <arm_group_label>001</arm_group_label>
    <arm_group_label>005</arm_group_label>
    <arm_group_label>006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Placebo will be administered as a single Intravenous infusion at week 0.</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 90 mg SC q8w</intervention_name>
    <description>Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.</description>
    <arm_group_label>003</arm_group_label>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 130 mg IV</intervention_name>
    <description>Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.</description>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab 90 mg SC q12w</intervention_name>
    <description>Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.</description>
    <arm_group_label>002</arm_group_label>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received study agent at the start of study CNTO1275CRD3001 or
             CNTO1275CRD3002 and completed the Week 8 visit. Exclusion Criteria:

          -  Patients who underwent a Crohn's disease-related surgery since the start of induction
             study CNTO1275CRD3001 or CNTO1275CRD3002

          -  Patients who started a protocol prohibited medication since the start of studies
             CNTO1275CRD3001 and CNTO1275CRD3002

          -  Patients with protocol-specified changes to their concomitant medications due to
             Crohn's disease (due to lack of efficacy) since the start of studies CNTO1275CRD3001
             and CNTO1275CRD3002
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urbana</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Central Queensland M C</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti Nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haßloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lÿneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stade</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest N/A</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Békéscsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeksz Rd N/A</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirosaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohtsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakura</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uruma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokkaichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokosuka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grafton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hastings</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plenty</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town Western Cape</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottinghamshirecc</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shropshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <results_first_submitted>October 17, 2016</results_first_submitted>
  <results_first_submitted_qc>January 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <disposition_first_submitted>April 14, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 14, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2016</disposition_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ustekinumab</keyword>
  <keyword>Stelara, Moderately to severely active Crohn's Disease</keyword>
  <keyword>IBD, Crohn's</keyword>
  <keyword>UNITI</keyword>
  <keyword>colitis</keyword>
  <keyword>IL-12</keyword>
  <keyword>IL-23</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Out of 1282 participants enrolled,1 was excluded from study before assignment to arm/group due to deviation from Good Clinical Practice at 1 study site. Hence 1281 participants were analyzed. Total 397 participants who were in clinical response to ustekinumab induction were randomized in maintenance study and considered as primary population.</recruitment_details>
      <pre_assignment_details>Due to a stability issue with the batch of Intravenous (IV) drug (130 mg Ustekinumab), in November 2011 sponsor temporarily suspended dosing in induction studies (CRD3001 and CRD3002) and this maintenance study (CRD3003). All 3 studies were restarted with a 90 milligram per millilter (mg/mL) formulation for IV administration on 17 February 2012.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ustekinumab Induction Responders(UST-I-Rsp)Placebo Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study.</description>
        </group>
        <group group_id="P2">
          <title>UST-I-Rsp-UST-90 mg Every 12 Weeks (Q12W) Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 milligrams (mg) q12w in the maintenance study.</description>
        </group>
        <group group_id="P3">
          <title>UST-I-Rsp-UST-90 mg Q8W Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q8w in the maintenance study.</description>
        </group>
        <group group_id="P4">
          <title>Placebo (PBO)-I-Rsp - PBO Maintenance</title>
          <description>Participants (who were in clinical response to placebo IV at Week 8 of an induction study) received placebo SC q4w in the maintenance study.</description>
        </group>
        <group group_id="P5">
          <title>PBO-I-nonRsp - UST-130mg Intravenous/90mg SC Q12W Maintenance</title>
          <description>Participants (who were not in clinical response to placebo IV at Week 8 of an induction study) received Ustekinumab 130 mg IV on entry into maintenance followed by Ustekinumab 90 mg SC q12 weeks beginning at Week 8 of maintenance (if in response).</description>
        </group>
        <group group_id="P6">
          <title>UST-I-nonRsp - UST-90mg Subcutaneously (SC) Q8W Maintenance</title>
          <description>Participants (who were not in clinical response to Ustekinumab IV at Week 8 of an induction study) received Ustekinumab 90 mg SC on entry into maintenance followed by Ustekinumab 90 mg SC q8w beginning at Week 8 of maintenance (if in response).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="123"/>
                <participants group_id="P5" count="285"/>
                <participants group_id="P6" count="476"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="131"/>
                <participants group_id="P4" count="123"/>
                <participants group_id="P5" count="285"/>
                <participants group_id="P6" count="476"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="131"/>
                <participants group_id="P6" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="154"/>
                <participants group_id="P6" count="272"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="126"/>
                <participants group_id="P6" count="217"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ustekinumab Induction Responders(UST-I-Rsp)Placebo Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study.</description>
        </group>
        <group group_id="B2">
          <title>UST-I-Rsp-UST-90 mg Every 12 Weeks (Q12W) Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 milligrams (mg) q12w in the maintenance study.</description>
        </group>
        <group group_id="B3">
          <title>UST-I-Rsp-UST-90 mg Q8W Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q8w in the maintenance study.</description>
        </group>
        <group group_id="B4">
          <title>Placebo (PBO)-I-Rsp - PBO Maintenance</title>
          <description>Participants (who were in clinical response to placebo IV at Week 8 of an induction study) received placebo SC q4w in the maintenance study.</description>
        </group>
        <group group_id="B5">
          <title>PBO-I-nonRsp - UST-130mg Intravenous/90mg SC Q12W Maintenance</title>
          <description>Participants (who were not in clinical response to placebo IV at Week 8 of an induction study) received Ustekinumab 130 mg IV on entry into maintenance followed by Ustekinumab 90 mg SC q12 weeks beginning at Week 8 of maintenance (if in response).</description>
        </group>
        <group group_id="B6">
          <title>UST-I-nonRsp - UST-90mg Subcutaneously (SC) Q8W Maintenance</title>
          <description>Participants (who were not in clinical response to Ustekinumab IV at Week 8 of an induction study) received Ustekinumab 90 mg SC on entry into maintenance followed by Ustekinumab 90 mg SC q8w beginning at Week 8 of maintenance (if in response).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="132"/>
            <count group_id="B4" value="123"/>
            <count group_id="B5" value="285"/>
            <count group_id="B6" value="476"/>
            <count group_id="B7" value="1281"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="12.69"/>
                    <measurement group_id="B2" value="38.6" spread="13.65"/>
                    <measurement group_id="B3" value="37.9" spread="13.2"/>
                    <measurement group_id="B4" value="39.1" spread="12.46"/>
                    <measurement group_id="B5" value="39" spread="12.33"/>
                    <measurement group_id="B6" value="37.4" spread="12.5"/>
                    <measurement group_id="B7" value="38.3" spread="12.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="149"/>
                    <measurement group_id="B6" value="275"/>
                    <measurement group_id="B7" value="712"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="136"/>
                    <measurement group_id="B6" value="201"/>
                    <measurement group_id="B7" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iceland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Democratic People'S Republic Of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="124"/>
                    <measurement group_id="B6" value="198"/>
                    <measurement group_id="B7" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Remission at Week 44</title>
        <description>Clinical remission at Week 44 was defined as a Crohn’s Disease Activity Index (CDAI) score of &lt;150 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). CDAI was assessed by collecting information on 8 different Crohn’s disease-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). A decrease in CDAI over time indicates improvement in disease activity.</description>
        <time_frame>Week 44</time_frame>
        <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Subcutaneously (SC)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q12w in the maintenance study.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg SC q8w</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q8w in the maintenance study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Remission at Week 44</title>
          <description>Clinical remission at Week 44 was defined as a Crohn’s Disease Activity Index (CDAI) score of &lt;150 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). CDAI was assessed by collecting information on 8 different Crohn’s disease-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). A decrease in CDAI over time indicates improvement in disease activity.</description>
          <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission at Week 0, ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission at Week 0, ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Response at Week 44</title>
        <description>Clinical response at Week 44 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (&gt;=) 100 points. Participants with a baseline CDAI score of &gt; = 220 to less than or equal (&lt; =) 248 were considered to be in clinical response if a CDAI score of less than (&lt;) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity.</description>
        <time_frame>Week 44</time_frame>
        <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Subcutaneously (SC)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q12w in the maintenance study.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg SC q8w</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q8w in the maintenance study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response at Week 44</title>
          <description>Clinical response at Week 44 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (&gt;=) 100 points. Participants with a baseline CDAI score of &gt; = 220 to less than or equal (&lt; =) 248 were considered to be in clinical response if a CDAI score of less than (&lt;) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity.</description>
          <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission at Week 0, ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission at Week 0, ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Clinical Remission at Week 44 Among Participants in Clinical Remission to Ustekinumab at Week 0 of Maintenance Study</title>
        <description>Clinical remission at week 44 was defined as a CDAI score of &lt; 150 points among participants in clinical remission to Ustekinumab at week 0 of maintenance study.</description>
        <time_frame>Week 44</time_frame>
        <population>Analysis population included all randomized participants after the study was restarted (who were in clinical remission at Week 0 of maintenance study). 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Subcutaneously (SC)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q12w in the maintenance study.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg SC q8w</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q8w in the maintenance study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Clinical Remission at Week 44 Among Participants in Clinical Remission to Ustekinumab at Week 0 of Maintenance Study</title>
          <description>Clinical remission at week 44 was defined as a CDAI score of &lt; 150 points among participants in clinical remission to Ustekinumab at week 0 of maintenance study.</description>
          <population>Analysis population included all randomized participants after the study was restarted (who were in clinical remission at Week 0 of maintenance study). 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.189</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Corticosteroid-free Remission at Week 44</title>
        <description>Corticosteroid-free remission at Week 44 was defined as a CDAI score of &lt;150 points without receiving corticosteroids at Week 44.</description>
        <time_frame>Week 44</time_frame>
        <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Subcutaneously (SC)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q12w in the maintenance study.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg SC q8w</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q8w in the maintenance study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Corticosteroid-free Remission at Week 44</title>
          <description>Corticosteroid-free remission at Week 44 was defined as a CDAI score of &lt;150 points without receiving corticosteroids at Week 44.</description>
          <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission at Week 0, ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2-sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission at Week 0, ustekinumab induction dose and the induction study.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Clinical Remission at Week 44 in the Subset of Participants Who Were Refractory or Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy</title>
        <description>Clinical remission at Week 44 was defined as a CDAI score of &lt;150 points in the subset of participants who were refractory or Intolerant to tumor necrosis factor antagonist therapy.</description>
        <time_frame>Week 44</time_frame>
        <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Subcutaneously (SC)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study.</description>
          </group>
          <group group_id="O2">
            <title>Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q12w in the maintenance study.</description>
          </group>
          <group group_id="O3">
            <title>Ustekinumab 90 mg SC q8w</title>
            <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) randomized to receive Ustekinumab SC 90 mg q8w in the maintenance study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Clinical Remission at Week 44 in the Subset of Participants Who Were Refractory or Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy</title>
          <description>Clinical remission at Week 44 was defined as a CDAI score of &lt;150 points in the subset of participants who were refractory or Intolerant to tumor necrosis factor antagonist therapy.</description>
          <population>The primary efficacy analysis population in this study was randomized participants (ie, participants who were in clinical response to ustekinumab induction dosing at Week 8 from one of the induction studies CRD3001 and CRD3002) after study restart.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2 sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission status at Week 0 and ustekinumab induction dose.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <p_value_desc>A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.</p_value_desc>
            <method>Cochran-Mantel-Haenszel chi-square test</method>
            <method_desc>2 sided Cochran-Mantel-Haenszel chi-square test, stratified by clinical remission status at Week 0 and ustekinumab induction dose.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 44</time_frame>
      <desc>Randomized participants (Placebo, ustekinumab 90 mg every 12 weeks [q12w] and ustekinumab 90 mg q8w ) in maintenance study, who subsequently lost response at any scheduled visit between Week 8 and Week 32 were eligible to have dose adjustment to ustekinumab 90 mg Subcutaneous (SC) for q8w.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ustekinumab Induction Responders(USTIRsp) Placebo Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) received placebo subcutaneously (SC) every 4 weeks (q4w) in the maintenance study (includes events up to the time of loss of response).</description>
        </group>
        <group group_id="E2">
          <title>UST -I-Rsp -PBO Maintenance -UST-90mg SC Q8W- Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) received placebo SC and had dose adjustment to Ustekinumab SC 90 mg q8w (includes events from the time of loss of response onward).</description>
        </group>
        <group group_id="E3">
          <title>UST-I-Rsp-UST 90 mg SC Every 12 Weeks (Q12W) Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) received Ustekinumab SC 90 milligrams (mg) q12w in the maintenance study (includes events up to the time of loss of response).</description>
        </group>
        <group group_id="E4">
          <title>UST-I-Rsp-UST 90 mg SC Q12W/Q8W Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) received Ustekinumab SC 90 mg q12w and had dose adjustment to Ustekinumab SC 90 mg q8w in the maintenance study (includes events from the time of loss of response onward).</description>
        </group>
        <group group_id="E5">
          <title>UST-I-Rsp-UST 90 mg SC Q8W Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) received Ustekinumab SC 90 mg q8w (includes events up to the time of loss of response).</description>
        </group>
        <group group_id="E6">
          <title>UST IV-I-Rsp-UST-90mg Maintenance-UST-90mg SC Q8W Maintenance</title>
          <description>Participants (who were in clinical response to Ustekinumab IV at Week 8 of an induction study) received Ustekinumab SC 90 mg q8 weeks and remained on ustekinumab 90 mg q8w upon loss of response (includes events from the time of loss of response onward).</description>
        </group>
        <group group_id="E7">
          <title>Placebo (PBO)-I-Rsp PBO Maintenance</title>
          <description>Participants (who were in clinical response to placebo IV at Week 8 of an induction study) received placebo SC; not randomized.</description>
        </group>
        <group group_id="E8">
          <title>PBO-I-nonRsp- UST-130mg Intravenous/90mg SC Q12W Maintenance</title>
          <description>Participants (who were not in clinical response to placebo IV at Week 8 of an induction study) received Ustekinumab 130 mg IV on entry into maintenance followed by Ustekinumab 90 mg SC q12 weeks beginning at Week 8 of maintenance (if in response); not randomized.</description>
        </group>
        <group group_id="E9">
          <title>UST IV-I-nonRsp - UST-90 mg SC Q8W Maintenance</title>
          <description>Participants (who were not in clinical response to Ustekinumab IV at Week 8 of an induction study) received Ustekinumab 90 mg SC on entry into maintenance followed by Ustekinumab 90 mg SC q8w beginning at Week 8 of maintenance (if in response); not randomized.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="47" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="76" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="30" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Cyclic Vomiting Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Enterocutaneous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Enterovesical Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Faecal Volume Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Intestinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Large Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Large Intestinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Small Intestinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Campylobacter Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Hepatitis Infectious Mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Ophthalmic Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Perirectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Pneumonia Pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Pneumonia Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Rectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Allergic Transfusion Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Anastomotic Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Heat Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Sternal Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Electrolytes Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroadenoma of Breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Ovarian Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Small Intestine Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Female Genital Tract Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Breast Prosthesis User</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Substance Abuser</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Essential Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="80" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="156" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="264" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="38" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="40" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="46" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="33" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="51" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="33" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="48" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="40" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="26" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="476"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="476"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The global study was interrupted due to issues with the clinical supply.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

